Today: 19 July 2026
UiPath stock set for Jan. 2 open after CEO share sale, S&P MidCap 400 entry looms (PATH)
2 January 2026
2 mins read

UiPath stock set for Jan. 2 open after CEO share sale, S&P MidCap 400 entry looms (PATH)

NEW YORK, January 1, 2026, 20:45 ET — Market closed.

  • UiPath shares last closed at $16.39, down 1.7%, in the most recent session on Dec. 31.
  • A filing showed CEO Daniel Dines sold 90,000 shares for about $1.5 million under a pre-set trading plan.
  • UiPath is slated to join the S&P MidCap 400 before Friday’s open, a shift that can drive index-fund rebalancing flows.

UiPath Inc. shares ended the last trading day of 2025 down 1.7% at $16.39, after a regulatory filing showed Chief Executive Daniel Dines sold another block of stock. The shares were last at $16.34 in after-hours trading.

U.S. stock markets were shut on Thursday for the New Year’s Day holiday and reopen on Friday, putting the focus on how the stock trades when normal liquidity returns.

The timing is sensitive because UiPath is scheduled to join the S&P MidCap 400 before Friday’s opening bell, replacing Synovus Financial as Pinnacle Financial Partners moves to acquire it, S&P Dow Jones Indices said. In plain English, funds that mirror the index may need to buy UiPath shares to match the benchmark, which can create one-off demand around the rebalance.

A Form 4 filing showed Dines sold 45,000 shares on Dec. 30 and another 45,000 shares on Dec. 31, for total proceeds of about $1.5 million. The filing said the trades were executed under a Rule 10b5-1 plan, a pre-arranged program that lets executives trade on a set schedule.

Dines directly held 28.48 million shares after the transactions, the filing showed, and reported another 9.62 million shares held indirectly through Ice Vulcan Holding.

The stock has churned since a late-December pop tied to the index move, and Wednesday’s session drew heavy volume of about 69.6 million shares. Traders often view that mix—big volume and a lower close—as a sign of positioning ahead of a known catalyst.

Investors are also stepping into 2026 focused on artificial-intelligence spending and the path of U.S. interest rates—two forces that can swing valuations for software companies like UiPath. “For another year of strong double-digit percentage returns, markets need everything firing on all cylinders,” said Sam Stovall, chief investment strategist at CFRA. Reuters

UiPath sells enterprise automation software that helps businesses run repetitive digital tasks—often called robotic process automation, or RPA—alongside newer AI-driven workflows.

For UiPath traders, Friday’s open will test whether index-related buying can offset the negative signal some investors take from insider sales, even when they are pre-planned and disclosed after the fact.

Before the next session, attention will be on the opening auction and any outsized imbalance tied to the MidCap 400 rebalance. A return to the $17 area would suggest the index effect is dominating the tape, while sustained trade around the mid-$16 range would signal investors are leaning more heavily on the insider-selling headline.

UiPath’s investor relations calendar lists no upcoming events, leaving the next firm-specific catalyst as the company’s next earnings date and any update to guidance.

On the macro side, traders are bracing for a run of U.S. data next week, including the December employment report on Jan. 9 and inflation data the following week—prints that can move rate expectations and, by extension, high-growth software stocks.

Khadija Saeed is a financial markets reporter at TS2.tech, specializing in stocks, technology and emerging industries. She studied economics and finance at the London School of Economics and previously worked in market research before moving into financial journalism. Her coverage focuses on the companies, innovations and economic trends influencing global investors. Follow Khadija Saeed on Google News.

Stock Market Today

  • CSL Recovers A$16 Billion in Value, Trails Plasma Sector Gains This Week
    July 19, 2026, 3:25 PM EDT. CSL Limited (ASX:CSL) finished July 17 at A$123.32, rising 1.12% on the session and 0.35% for the week, recovering 37% from its 52-week low at A$90 and regaining roughly A$16 billion in valuation. However, CSL underperformed plasma specialists Grifols SA (+1.95%) and Takeda Pharmaceutical (+2.26%) in weekly movement. Trading volume for CSL on Friday came in 14% under its average as 1.62 million shares changed hands. The full-year financial results are due August 18. Still 55% beneath its 52-week peak, CSL's market value stands at A$59.06 billion. The group forecasts FY26 revenues near US$15.2 billion and NPATA of about US$3.1 billion, while a US$5 billion impairment remains subject to audit and board sign-off.
Chevron stock today: CVX steadies near $152 as oil logs steepest annual drop since 2020
Previous Story

Chevron stock today: CVX steadies near $152 as oil logs steepest annual drop since 2020

Nvidia stock today: China H200 supply push puts NVDA back in focus
Next Story

Nvidia stock today: China H200 supply push puts NVDA back in focus

Go toTop